Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Can direct-to-consumer advertising of prescription drugs be effectively regulated?

Lexchin J, Menkes DB.

N Z Med J. 2019 Jun 7;132(1496):59-65.

PMID:
31170134
2.

Innovation and off-label use, the French case and more.

Braillon A, Lexchin J.

Br J Clin Pharmacol. 2019 Jun 4. doi: 10.1111/bcp.13993. [Epub ahead of print] No abstract available.

PMID:
31161633
3.

Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study.

Lexchin J.

CMAJ Open. 2019 May 19;7(2):E334-E340. doi: 10.9778/cmajo.20190010. Print 2019 Apr-Jun.

4.

Pharmaceutical Industry-Initiated Postapproval Studies-Not Requested by the US FDA, Little Value, and Many Questions.

Lexchin J.

JAMA Netw Open. 2019 May 3;2(5):e193392. doi: 10.1001/jamanetworkopen.2019.3392. No abstract available.

PMID:
31074805
5.

The "pharmaceuticalisation" of life.

Braillon A, Lexchin J, Blumsohn A, Hengartner MP.

BMJ. 2019 May 8;365:l1972. doi: 10.1136/bmj.l1972. No abstract available.

PMID:
31068329
6.

Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom.

Perry LT, Bhasale A, Fabbri A, Lexchin J, Puil L, Joarder M, Mintzes B.

JAMA Intern Med. 2019 Apr 29. doi: 10.1001/jamainternmed.2019.0294. [Epub ahead of print] No abstract available.

PMID:
31033999
7.

Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study.

Lexchin J.

Healthc Policy. 2019 Feb;14(3):10-18. doi: 10.12927/hcpol.2019.25796.

PMID:
31017862
8.

Canada finally opens up data on new drugs and devices.

Lexchin J, Herder M, Doshi P.

BMJ. 2019 Apr 17;365:l1825. doi: 10.1136/bmj.l1825. No abstract available.

PMID:
30996020
9.

Secret safety warnings on medicines: A case study of information access requests.

Torka M, Mintzes B, Bhasale A, Fabbri A, Perry L, Lexchin J.

Pharmacoepidemiol Drug Saf. 2019 Apr;28(4):551-555. doi: 10.1002/pds.4762. Epub 2019 Mar 6.

PMID:
30840349
10.

Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.

Lexchin J.

PLoS One. 2019 Feb 15;14(2):e0212399. doi: 10.1371/journal.pone.0212399. eCollection 2019.

11.

Editorial.

Lexchin J.

J Popul Ther Clin Pharmacol. 2018 Sep 24;25(2):e31-e32. doi: 10.22374/1710-6222.25.2.4.

PMID:
30725541
12.

An International Mapping of Medical Care in Nursing Homes.

Ågotnes G, McGregor MJ, Lexchin J, Doupe MB, Müller B, Harrington C.

Health Serv Insights. 2019 Jan 23;12:1178632918825083. doi: 10.1177/1178632918825083. eCollection 2019.

13.

Challenging the promotion of antidepressants for nonsevere depression.

Braillon A, Lexchin J, Noble JH, Menkes D, M'sahli L, Fierlbeck K, Blumsohn A, Naudet F.

Acta Psychiatr Scand. 2019 Mar;139(3):294-295. doi: 10.1111/acps.13010. Epub 2019 Feb 8. No abstract available.

PMID:
30697690
14.

Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis.

Lexchin J.

Int J Health Serv. 2019 Apr;49(2):294-305. doi: 10.1177/0020731418821007. Epub 2018 Dec 26.

PMID:
30587064
15.

The term cognition-enhancing medications is misleading.

Lexchin JR.

Can Fam Physician. 2018 Nov;64(11):792. No abstract available.

16.

Cost recovery by Health Canada and drug safety: a time-series analysis.

Lexchin J.

CMAJ Open. 2018 Oct 18;6(4):E471-E477. doi: 10.9778/cmajo.20180146. Print 2018 Oct-Dec.

17.

Ten Principles for More Conservative, Care-Full Diagnosis.

Schiff GD, Martin SA, Eidelman DH, Volk LA, Ruan E, Cassel C, Galanter W, Johnson M, Jutel A, Kroenke K, Lambert BL, Lexchin J, Myers S, Miller A, Mushlin S, Sanders L, Sheikh A.

Ann Intern Med. 2018 Nov 6;169(9):643-645. doi: 10.7326/M18-1468. Epub 2018 Oct 2. No abstract available.

PMID:
30285046
18.

Canadian status of "drugs to avoid" in 2017: a descriptive analysis.

Lexchin J.

CMAJ Open. 2018 Sep 28;6(3):E430-E435. doi: 10.9778/cmajo.20180049. Print 2018 Jul-Sep.

19.
20.

Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence.

Wiktorowicz M, Moscou K, Lexchin J.

Global Health. 2018 Aug 22;14(1):86. doi: 10.1186/s12992-018-0402-5.

21.

Industry sponsorship and research outcome: systematic review with meta-analysis.

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.

Intensive Care Med. 2018 Oct;44(10):1603-1612. doi: 10.1007/s00134-018-5293-7. Epub 2018 Aug 21. Review.

PMID:
30132025
22.

Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.

Grootendorst P, Shim M, Falconi A, Robinson T, Lexchin J.

Int J Health Serv. 2018 Oct;48(4):702-715. doi: 10.1177/0020731418789610. Epub 2018 Jul 24.

PMID:
30040005
23.

A call to mandate patient access to personal primary care medical records across Canada.

Gorfinkel I, Lexchin J.

CMAJ. 2018 Jul 23;190(29):E869-E870. doi: 10.1503/cmaj.180522. No abstract available.

PMID:
30037887
24.

Healing an ailing pharmaceutical system: prescription for reform for United States and Canada.

Gaffney A, Lexchin J; US; Canadian Pharmaceutical Policy Reform Working Group.

BMJ. 2018 May 17;361:k1039. doi: 10.1136/bmj.k1039. Review. No abstract available.

PMID:
29773533
25.

Medicines Information and the Regulation of the Promotion of Pharmaceuticals.

Leonardo Alves T, Lexchin J, Mintzes B.

Sci Eng Ethics. 2018 May 2. doi: 10.1007/s11948-018-0041-5. [Epub ahead of print]

PMID:
29721844
26.

The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries.

Gleeson D, Lexchin J, Lopert R, Kilic B.

Glob Soc Policy. 2018 Apr;18(1):7-27. doi: 10.1177/1468018117734153. Epub 2017 Oct 13.

28.

Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study.

Banerjee A, James R, McGregor M, Lexchin J.

Can J Aging. 2018 Jun;37(2):133-144. doi: 10.1017/S0714980818000089. Epub 2018 Apr 5.

PMID:
29618397
29.

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis.

Lexchin J.

J Pharm Policy Pract. 2018 Mar 13;11:5. doi: 10.1186/s40545-018-0132-3. eCollection 2018.

30.

Combating corruption in the pharmaceutical arena.

Lexchin J, Kohler JC, Gagnon MA, Crombie J, Thacker P, Shnier A.

Indian J Med Ethics. 2018 Jul-Sep;3(3):234-239. doi: 10.20529/IJME.2018.022. Epub 2018 Mar 15.

31.

Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care.

Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B.

Health Policy. 2018 Mar;122(3):250-255. doi: 10.1016/j.healthpol.2018.01.010. Epub 2018 Feb 1.

PMID:
29395543
32.

Composition of Canadian Pain Society guideline development group?

Lexchin JR.

Can Fam Physician. 2018 Jan;64(1):8. No abstract available.

33.

We need to mandate drug cost transparency on electronic medical records.

Gorfinkel I, Lexchin J.

CMAJ. 2017 Dec 18;189(50):E1541-E1542. doi: 10.1503/cmaj.171070. No abstract available.

34.

Financial costs associated with monopolies on biologic medicines in Australia.

Gleeson D, Townsend B, Lopert R, Lexchin J, Moir H.

Aust Health Rev. 2019 Feb;43(1):36-42. doi: 10.1071/AH17031.

PMID:
29116927
35.

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.

Lexchin J.

BMJ Open. 2017 Oct 22;7(10):e018372. doi: 10.1136/bmjopen-2017-018372.

36.

Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.

Lexchin J.

Value Health. 2017 Sep;20(8):1139-1142. doi: 10.1016/j.jval.2017.05.004. Epub 2017 Jun 20.

37.

The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis.

Lexchin J.

CMAJ Open. 2017 Sep 13;5(3):E724-E728. doi: 10.9778/cmajo.20170089.

38.
39.

Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST.

Shaughnessy AF, Vaswani A, Andrews BK, Erlich DR, D'Amico F, Lexchin J, Cosgrove L.

Ann Fam Med. 2017 Sep;15(5):413-418. doi: 10.1370/afm.2119.

40.
41.

Priority reviews: innovation and safety.

Lexchin J.

CMAJ. 2017 Jul 4;189(26):E895. doi: 10.1503/cmaj.733103. No abstract available.

42.

Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

Habibi R, Lexchin J, Mintzes B, Holbrook A.

Br J Clin Pharmacol. 2017 Nov;83(11):2549-2556. doi: 10.1111/bcp.13360. Epub 2017 Aug 19.

43.

Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.

Habibi R, Guénette L, Lexchin J, Reynolds E, Wiktorowicz M, Mintzes B.

J Law Med Ethics. 2016 Dec;44(4):602-613. doi: 10.1177/1073110516684803.

PMID:
28661249
44.

Drug prices: How do we get to a better place?

Lexchin J.

CMAJ. 2017 Jun 12;189(23):E792-E793. doi: 10.1503/cmaj.170440. No abstract available.

45.

Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder.

Cosgrove L, Shaughnessy AF, Peters SM, Lexchin JR, Bursztajn H, Bero L.

Psychother Psychosom. 2017;86(3):168-170. doi: 10.1159/000458727. Epub 2017 May 11. No abstract available.

PMID:
28490018
46.

Medicines Save, Medicines Kill.

Lexchin J.

Drug Saf. 2017 Jun;40(6):457-459. doi: 10.1007/s40264-017-0521-6. No abstract available.

PMID:
28315139
47.

Industry sponsorship and research outcome.

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L.

Cochrane Database Syst Rev. 2017 Feb 16;2:MR000033. doi: 10.1002/14651858.MR000033.pub3. Review.

PMID:
28207928
48.

Six Myths About Pharmacare.

Lexchin J.

Health Law Can. 2017 Feb;37(2-3):44-51.

PMID:
30005520
49.

The Need to Systematically Evaluate Clinical Practice Guidelines.

Shaughnessy AF, Cosgrove L, Lexchin JR.

J Am Board Fam Med. 2016 Nov 12;29(6):644-648. doi: 10.3122/jabfm.2016.06.160115.

50.

Supplemental Content

Loading ...
Support Center